Logo image of ALERS.PA

EUROBIO-SCIENTIFIC (ALERS.PA) Stock Fundamental Analysis

EPA:ALERS - Euronext Paris - Matif - FR0013240934 - Common Stock - Currency: EUR

25.35  +0.05 (+0.2%)

Fundamental Rating

6

ALERS gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 71 industry peers in the Biotechnology industry. ALERS scores excellent points on both the profitability and health parts. This is a solid base for a good stock. ALERS is not valued too expensively and it also shows a decent growth rate. With these ratings, ALERS could be worth investigating further for quality investing!.


Dividend Valuation Growth Profitability Health

Quickly go to:

7

1. Profitability

1.1 Basic Checks

ALERS had positive earnings in the past year.
ALERS had a positive operating cash flow in the past year.
ALERS had positive earnings in each of the past 5 years.
ALERS had a positive operating cash flow in each of the past 5 years.
ALERS.PA Yearly Net Income VS EBIT VS OCF VS FCFALERS.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M 40M 60M 80M

1.2 Ratios

The Return On Assets of ALERS (2.12%) is better than 77.46% of its industry peers.
Looking at the Return On Equity, with a value of 3.72%, ALERS is in the better half of the industry, outperforming 78.87% of the companies in the same industry.
ALERS has a better Return On Invested Capital (4.16%) than 81.69% of its industry peers.
The Average Return On Invested Capital over the past 3 years for ALERS is in line with the industry average of 13.59%.
The last Return On Invested Capital (4.16%) for ALERS is well below the 3 year average (14.53%), which needs to be investigated, but indicates that ALERS had better years and this may not be a problem.
Industry RankSector Rank
ROA 2.12%
ROE 3.72%
ROIC 4.16%
ROA(3y)12.64%
ROA(5y)16.89%
ROE(3y)18.31%
ROE(5y)26.49%
ROIC(3y)14.53%
ROIC(5y)18.91%
ALERS.PA Yearly ROA, ROE, ROICALERS.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40 -40 60 -60

1.3 Margins

With a decent Profit Margin value of 4.61%, ALERS is doing good in the industry, outperforming 77.46% of the companies in the same industry.
ALERS's Profit Margin has declined in the last couple of years.
The Operating Margin of ALERS (9.75%) is better than 80.28% of its industry peers.
ALERS's Operating Margin has declined in the last couple of years.
ALERS has a Gross Margin (46.75%) which is in line with its industry peers.
In the last couple of years the Gross Margin of ALERS has grown nicely.
Industry RankSector Rank
OM 9.75%
PM (TTM) 4.61%
GM 46.75%
OM growth 3Y-36.17%
OM growth 5YN/A
PM growth 3Y-54.28%
PM growth 5YN/A
GM growth 3Y-6.94%
GM growth 5Y5.2%
ALERS.PA Yearly Profit, Operating, Gross MarginsALERS.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20 -20 40

More info and screens

7

2. Health

2.1 Basic Checks

ALERS has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
Compared to 1 year ago, ALERS has less shares outstanding
The number of shares outstanding for ALERS has been increased compared to 5 years ago.
The debt/assets ratio for ALERS has been reduced compared to a year ago.
ALERS.PA Yearly Shares OutstandingALERS.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
ALERS.PA Yearly Total Debt VS Total AssetsALERS.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

An Altman-Z score of 2.81 indicates that ALERS is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a decent Altman-Z score value of 2.81, ALERS is doing good in the industry, outperforming 78.87% of the companies in the same industry.
ALERS has a debt to FCF ratio of 4.71. This is a neutral value as ALERS would need 4.71 years to pay back of all of its debts.
With an excellent Debt to FCF ratio value of 4.71, ALERS belongs to the best of the industry, outperforming 87.32% of the companies in the same industry.
ALERS has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
ALERS's Debt to Equity ratio of 0.44 is in line compared to the rest of the industry. ALERS outperforms 56.34% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 4.71
Altman-Z 2.81
ROIC/WACC0.55
WACC7.5%
ALERS.PA Yearly LT Debt VS Equity VS FCFALERS.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 2.69 indicates that ALERS has no problem at all paying its short term obligations.
ALERS's Current ratio of 2.69 is fine compared to the rest of the industry. ALERS outperforms 60.56% of its industry peers.
ALERS has a Quick Ratio of 2.26. This indicates that ALERS is financially healthy and has no problem in meeting its short term obligations.
ALERS has a Quick ratio of 2.26. This is comparable to the rest of the industry: ALERS outperforms 57.75% of its industry peers.
Industry RankSector Rank
Current Ratio 2.69
Quick Ratio 2.26
ALERS.PA Yearly Current Assets VS Current LiabilitesALERS.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for ALERS have decreased strongly by -15.70% in the last year.
The earnings per share for ALERS have been decreasing by -59.58% on average. This is quite bad
The Revenue has grown by 12.58% in the past year. This is quite good.
Measured over the past years, ALERS shows a very strong growth in Revenue. The Revenue has been growing by 20.80% on average per year.
EPS 1Y (TTM)-15.7%
EPS 3Y-59.58%
EPS 5YN/A
EPS Q2Q%105.99%
Revenue 1Y (TTM)12.58%
Revenue growth 3Y-11.7%
Revenue growth 5Y20.8%
Sales Q2Q%23.86%

3.2 Future

ALERS is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 21.14% yearly.
The Revenue is expected to grow by 8.18% on average over the next years. This is quite good.
EPS Next Y-2.22%
EPS Next 2Y13.53%
EPS Next 3Y21.14%
EPS Next 5YN/A
Revenue Next Year6.07%
Revenue Next 2Y7.77%
Revenue Next 3Y8.18%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ALERS.PA Yearly Revenue VS EstimatesALERS.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
ALERS.PA Yearly EPS VS EstimatesALERS.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 4 6

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

ALERS is valuated quite expensively with a Price/Earnings ratio of 39.61.
Based on the Price/Earnings ratio, ALERS is valued cheaper than 80.28% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 24.12, ALERS is valued quite expensively.
ALERS is valuated rather expensively with a Price/Forward Earnings ratio of 21.22.
Based on the Price/Forward Earnings ratio, ALERS is valued cheaper than 85.92% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 20.42. ALERS is around the same levels.
Industry RankSector Rank
PE 39.61
Fwd PE 21.22
ALERS.PA Price Earnings VS Forward Price EarningsALERS.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80 100

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of ALERS indicates a rather cheap valuation: ALERS is cheaper than 88.73% of the companies listed in the same industry.
90.14% of the companies in the same industry are more expensive than ALERS, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 13.02
EV/EBITDA 9.22
ALERS.PA Per share dataALERS.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

The decent profitability rating of ALERS may justify a higher PE ratio.
ALERS's earnings are expected to grow with 21.14% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.53%
EPS Next 3Y21.14%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALERS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EUROBIO-SCIENTIFIC

EPA:ALERS (5/8/2025, 7:00:00 PM)

25.35

+0.05 (+0.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)04-09 2025-04-09/amc
Earnings (Next)07-29 2025-07-29
Inst Owners4.94%
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap259.84M
Analysts84.44
Price Target30.6 (20.71%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE 39.61
Fwd PE 21.22
P/S 1.8
P/FCF 13.02
P/OCF 11.26
P/B 1.45
P/tB 9.19
EV/EBITDA 9.22
EPS(TTM)0.64
EY2.52%
EPS(NY)1.19
Fwd EY4.71%
FCF(TTM)1.95
FCFY7.68%
OCF(TTM)2.25
OCFY8.88%
SpS14.06
BVpS17.43
TBVpS2.76
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 2.12%
ROE 3.72%
ROCE 5.42%
ROIC 4.16%
ROICexc 6.24%
ROICexgc 48.46%
OM 9.75%
PM (TTM) 4.61%
GM 46.75%
FCFM 13.85%
ROA(3y)12.64%
ROA(5y)16.89%
ROE(3y)18.31%
ROE(5y)26.49%
ROIC(3y)14.53%
ROIC(5y)18.91%
ROICexc(3y)31.05%
ROICexc(5y)40.03%
ROICexgc(3y)76.58%
ROICexgc(5y)85.22%
ROCE(3y)19.05%
ROCE(5y)24.73%
ROICexcg growth 3Y-35.22%
ROICexcg growth 5YN/A
ROICexc growth 3Y-60.78%
ROICexc growth 5YN/A
OM growth 3Y-36.17%
OM growth 5YN/A
PM growth 3Y-54.28%
PM growth 5YN/A
GM growth 3Y-6.94%
GM growth 5Y5.2%
F-Score7
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF 4.71
Debt/EBITDA 2.71
Cap/Depr 20.88%
Cap/Sales 2.16%
Interest Coverage 250
Cash Conversion 79.6%
Profit Quality 300.41%
Current Ratio 2.69
Quick Ratio 2.26
Altman-Z 2.81
F-Score7
WACC7.5%
ROIC/WACC0.55
Cap/Depr(3y)28.59%
Cap/Depr(5y)28.36%
Cap/Sales(3y)1.99%
Cap/Sales(5y)1.98%
Profit Quality(3y)245.65%
Profit Quality(5y)183.27%
High Growth Momentum
Growth
EPS 1Y (TTM)-15.7%
EPS 3Y-59.58%
EPS 5YN/A
EPS Q2Q%105.99%
EPS Next Y-2.22%
EPS Next 2Y13.53%
EPS Next 3Y21.14%
EPS Next 5YN/A
Revenue 1Y (TTM)12.58%
Revenue growth 3Y-11.7%
Revenue growth 5Y20.8%
Sales Q2Q%23.86%
Revenue Next Year6.07%
Revenue Next 2Y7.77%
Revenue Next 3Y8.18%
Revenue Next 5YN/A
EBIT growth 1Y-14.9%
EBIT growth 3Y-43.64%
EBIT growth 5YN/A
EBIT Next Year19.3%
EBIT Next 3Y18.15%
EBIT Next 5YN/A
FCF growth 1Y-66.71%
FCF growth 3Y-24.43%
FCF growth 5YN/A
OCF growth 1Y-62.47%
OCF growth 3Y-21.31%
OCF growth 5YN/A